Catherine Schuster-Bruce

• Medical doctor • Award-winning journalist words @businessinsider @hsj • Consultant °Views mine °Instagram @drcatherinesb

[Catherine Schuster-Bruce @drcatherinesb]

Very excited to announce that I’ve joined the team as Business Insider’s first UK healthcare reporter! I’ll be covering European healthcare business for @businessinsider, closely tracking vaccines, start-ups and everything digital health. My DMs are open - go!

[Catherine Schuster-Bruce @drcatherinesb]

@psychglobal_ @dramirinamdar Such a great chat around the challenges (and opportunities) in psychedelic drug development! 👏

[Catherine Schuster-Bruce @drcatherinesb]

@jesse_yeji and I asked VCs in psychedelics to name the most promising startups in the field.

Click through to see the companies that made the list (and why)!

Are there others that you're excited about? Why?
https://t.co/23M7mEoiyl

[Catherine Schuster-Bruce @drcatherinesb]

The hottest startups in psychedelics, according to investors 👀👀👀

It's been a tough market for the psychedelics industry. But, during the downturn, venture capitalists are continuing to invest in companies they say are promising...

[Catherine Schuster-Bruce @drcatherinesb]

The final list have invested about $347 million altogether in recent years. https://t.co/J6Iakgmt6g

[Catherine Schuster-Bruce @drcatherinesb]

Meet the top VCs in the psychedelics space!

@jesse_yeji and I wanted to know who wrote the most cheques.

We asked around 25 firms how many deals they've made and how much money they've invested in the space, among other questions. (1)

[Catherine Schuster-Bruce @drcatherinesb]

We narrowed our list to 14 firms by including only funds that invested at least $5 million into psychedelics companies and had portfolios made up of at least 30% psychedelics startups.

[Catherine Schuster-Bruce @drcatherinesb]

@KeysToTheBank Hi Mike, I'm a journo from Insider. I hope you don't mind us contacting you. We've read about your story and would love to interview you about your experiences. I'm on [email protected] - thank you!

[Yeji Jesse Lee | 이예지 @jesse_yeji]

We don't rely on press releases/statements: every few months @drcatherinesb and I contact each company on our tracker & reach out to new ones to ask when we should expect more data, how their trials are faring, and how much $ they have on hand to continue backing their studies

[Nick Jikomes @trikomes]

🧵#ScienceBreakdown: "Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors"

Interesting new paper by @DEOlsonLab, @LinTianPhD, et al. looking at why some serotonin 2A receptor agonists promote neuroplasticity, but others do not.

1/

[Catherine Schuster-Bruce @drcatherinesb]

@KurteL10 Insider would love to speak with you, can you email [email protected]!

[Catherine Schuster-Bruce @drcatherinesb]

Well said https://t.co/w5iQDui53j

[Lydia Ramsey Pflanzer @lydiapflanzer]

It might be the middle of July, but the healthcare team @BusinessInsider has been busy this week putting out fascinating reads on the future of the industry. (thread!)

[Psychedelic Science @PsychedelicSci]

Who is creating a framework for Oregon's legalization of #psilocybin to happen?

@Jesse_Yeji & Dr. @DrCatherineSB of @ThisIsInsider are naming a few:

@MylesKatz;
@David_Bronner of @DrBronner;
@MasonMarksMD;
@KTuckerELLP;
@SherisEckert
and more.

https://t.co/yoX5IbRwGt

[Yeji Jesse Lee | 이예지 @jesse_yeji]

Here are some of the most influential regulators, advocates, and executives shaping the first ever regulated psilocybin market in the US.

Latest from me & @drcatherinesb:

https://t.co/u3iarlvtPJ

[Catherine Schuster-Bruce @drcatherinesb]

Who is deciding what legal "magic" mushrooms in the US might look like? We looked to Oregon to find out. https://t.co/dKBGpYtDnY @jesse_yeji @HealthInsider

[Catherine Schuster-Bruce @drcatherinesb]

@clairvoyantrx @jesse_yeji keep us in the loop!

[Catherine Schuster-Bruce @drcatherinesb]

There's hundreds of studies and a whole load of hype around the potential to transform compounds like MDMA and psilocybin into new medical treatments that might be prescribed to millions of people with health conditions for which there are few good options right now.. (A thread!)

[Yeji Jesse Lee | 이예지 @jesse_yeji]

We took a long hard look at the psychedelics clinical trials furthest along in the regulatory pathway and put together an analysis of what we found.

Latest from @drcatherinesb & me: (1/11)

https://t.co/f1alteWYrF

[Catherine Schuster-Bruce @drcatherinesb]

Putting all these reports together has been a mammoth team effort. Big big thank you to @ZTracer and the fantastic graphics team: Shayanne Gal, Annie Fu, and Alex Ford.

[Catherine Schuster-Bruce @drcatherinesb]

🤓🤓
https://t.co/y1dObMhNGu